ea0011p547 | Endocrine tumours and neoplasia | ECE2006
Ferolla P
, Faggiano A
, Pivonello R
, Lombardi G
, Angeletti G
, Colao A
, Santeusanio F
Introduction: Somatostatin analogues (SSA) represent the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumors (NET). However, after a variable time from the start of the therapy tachyphylaxys may cause lack of control of clinical syndrome and progression of the disease.Aim: The aim of this preliminary study was to evaluate efficacy in terms of reduction of circulating markers, control of the clinical syn...